Collegium Pharmaceutical (COLL) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool.

DATE

Thursday, Aug. 6, 2026 astatine 8:00 a.m. ET

CALL PARTICIPANTS

• Head of Investor Relations - Ian Karp

• President and Chief Executive Officer - Vikram Karnani

• Chief Financial Officer - Colleen Tupper

Full Conference Call Transcript

Operator: Greetings, and invited to the Collegium Pharmaceutical Second Quarter 2026 Earnings Conference Call. [Operator Instructions] Please enactment that this league telephone is being recorded. I would present similar to crook the telephone implicit to Ian Karp, Head of Investor Relations.

Ian Karp: Great. Thanks truthful much, and invited to Collegium Pharmaceutical's 2nd 4th 2026 net league call. I'm joined contiguous by Vikram Karnani, our President and Chief Executive Officer, and Colleen Tupper, our Chief Financial Officer. Before we statesman today's call, we privation to punctual participants that nary of the accusation presented contiguous is intended to beryllium promotional. Any forward-looking statements made contiguous are made pursuant to the Safe Harbor proviso of the Private Securities Litigation Reform Act of 1995. You are cautioned that specified forward-looking statements impact risks and uncertainties arsenic elaborate successful the company's periodic reports filed with the Securities and Exchange Commission. Our aboriginal results whitethorn disagree materially from our existent expectations discussed today.

Our net property merchandise and this telephone volition see treatment of definite non-GAAP information. You tin find our net property release, including applicable non-GAAP reconciliations, connected our firm website. And with that, I'll present crook the telephone implicit to our President and CEO, Vikram Karnani.

Vikram Karnani: Thank you, Ian. Good morning, everyone, and convey you for joining our 2nd 4th 2026 net call. Collegium is simply a dynamic biopharmaceutical institution delivering medicines with formulation and transportation innovation for radical surviving with analyzable CNS and symptom conditions. Today, we person a diversified portfolio of 6 differentiated medicines, a increasing ADHD franchise, and an established symptom concern that unneurotic supply a beardown instauration for semipermanent worth creation. We person a demonstrated quality to acquire, integrate, and turn differentiated assets portion deploying superior successful a disciplined manner. This quarter, we delivered beardown results, highlighted by important advancement successful our rapidly increasing ADHD business.

Key achievements included: Jornay PM prescriptions grew by 13.1%, generating $46.1 cardinal successful nett revenue, up 41% year-over-year. Jornay PM prescribers reached an all-time precocious with implicit 30,000 healthcare providers penning Jornay PM prescriptions successful the quarter, up 17.6% implicit Q2 of past year. And importantly, we completed the acquisition of Azstarys successful May, which present provides america with a differentiated and highly complementary medicine to Jornay PM. This latest acquisition further reinforces the strategy we initiated successful 2024 to diversify our portfolio beyond liable symptom absorption and found a beardown beingness successful the increasing ADHD market.